KESTRA MEDICAL TECHNOLOGIES, LTD. financial data

Symbol
KMTS on Nasdaq
Location
Kirkland, WA
Fiscal year end
30 April
Latest financial report
10-Q - Q3 2025 - 11 Dec 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58,349,053 shares
Common Stock, Shares, Outstanding 51,449,053 shares
Entity Public Float $0 USD
Common Stock, Value, Issued $51,449,000 USD
Weighted Average Number of Shares Outstanding, Basic 51,376,278 shares 158%
Weighted Average Number of Shares Outstanding, Diluted 51,376,278 shares 158%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $22,565,000 USD 53%
Research and Development Expense $4,878,000 USD 39%
Operating Income (Loss) $31,755,000 USD -66%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $32,751,000 USD -59%
Income Tax Expense (Benefit) $34,000 USD 325%
Net Income (Loss) Attributable to Parent $32,785,000 USD -61%
Earnings Per Share, Basic -0.64 USD/shares 46%
Earnings Per Share, Diluted -0.64 USD/shares 46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $175,424,000 USD 128%
Other Assets, Current $1,355,000 USD
Assets, Current $195,414,000 USD
Property, Plant and Equipment, Net $45,932,000 USD
Operating Lease, Right-of-Use Asset $1,960,000 USD
Other Assets, Noncurrent $1,203,000 USD
Assets $246,701,000 USD
Accounts Payable, Current $20,209,000 USD
Accrued Liabilities, Current $15,494,000 USD
Liabilities, Current $35,756,000 USD
Operating Lease, Liability, Noncurrent $2,874,000 USD
Other Liabilities, Noncurrent $140,000 USD
Liabilities $82,620,000 USD
Retained Earnings (Accumulated Deficit) $578,860,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $164,081,000 USD
Liabilities and Equity $246,701,000 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $26,274,000 USD -50%
Net Cash Provided by (Used in) Financing Activities $1,875,000 USD -102%
Net Cash Provided by (Used in) Investing Activities $8,232,000 USD -17%
Common Stock, Shares Authorized 100,000,000 shares
Common Stock, Shares, Issued 51,449,053 shares
Common Stock, Par or Stated Value Per Share 1 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $36,381,000 USD -140%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $175,758,000 USD 128%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,423,000 USD 17%
Deferred Tax Assets, Valuation Allowance $103,815,000 USD 31%
Deferred Tax Assets, Gross $110,698,000 USD 32%
Operating Lease, Liability $3,213,000 USD
Depreciation $2,372,000 USD 27%
Payments to Acquire Property, Plant, and Equipment $8,166,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid $4,549,000 USD
Property, Plant and Equipment, Gross $73,697,000 USD
Operating Lease, Liability, Current $53,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,364,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $333,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.152 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,336,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,405,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $52,281,000 USD 51%
Unrecognized Tax Benefits $819,000 USD 5.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,447,000 USD
Operating Lease, Payments $491,000 USD 198%
Depreciation, Depletion and Amortization $2,028,000 USD -15%
Deferred Tax Assets, Net of Valuation Allowance $6,883,000 USD 50%
Share-based Payment Arrangement, Expense $8,653,000 USD 671%